148 related articles for article (PubMed ID: 36166960)
1. Dynamics of cell-free DNA in predicting response in adult diffuse glioma on chemoradiotherapy.
Husain A; Mishra S; Hadi R; Sahu A; Kumari S; Rastogi M; Khurana R; Shukla S; Siddiqui MH; Husain N
Cancer Genet; 2022 Nov; 268-269():55-63. PubMed ID: 36166960
[TBL] [Abstract][Full Text] [Related]
2. High prevalence of clonal hematopoiesis-type genomic abnormalities in cell-free DNA in invasive gliomas after treatment.
Okamura R; Piccioni DE; Boichard A; Lee S; Jimenez RE; Sicklick JK; Kato S; Kurzrock R
Int J Cancer; 2021 Jun; 148(11):2839-2847. PubMed ID: 33497479
[TBL] [Abstract][Full Text] [Related]
3. Detection of IDH1 Mutation in cfDNA and Tissue of Adult Diffuse Glioma with Allele-Specific qPCR.
Husain A; Mishra S; Siddiqui MH; Husain N
Asian Pac J Cancer Prev; 2023 Mar; 24(3):961-968. PubMed ID: 36974551
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the mutation patterns between tumor tissue and cell-free DNA in stage IV gastric cancer.
Kung CY; Fang WL; Hung YP; Huang KH; Chen MH; Chao Y; Lin SC; Li AF; Lo SS; Wu CW
Aging (Albany NY); 2023 Feb; 15(3):777-790. PubMed ID: 36779847
[TBL] [Abstract][Full Text] [Related]
5. IDH1 mutation is detectable in plasma cell-free DNA and is associated with survival outcome in glioma patients.
Crucitta S; Pasqualetti F; Gonnelli A; Ruglioni M; Luculli GI; Cantarella M; Ortenzi V; Scatena C; Paiar F; Naccarato AG; Danesi R; Del Re M
BMC Cancer; 2024 Jan; 24(1):31. PubMed ID: 38172718
[TBL] [Abstract][Full Text] [Related]
6. Detection of gene mutations and gene-gene fusions in circulating cell-free DNA of glioblastoma patients: an avenue for clinically relevant diagnostic analysis.
Palande V; Siegal T; Detroja R; Gorohovski A; Glass R; Flueh C; Kanner AA; Laviv Y; Har-Nof S; Levy-Barda A; Viviana Karpuj M; Kurtz M; Perez S; Raviv Shay D; Frenkel-Morgenstern M
Mol Oncol; 2022 May; 16(10):2098-2114. PubMed ID: 34875133
[TBL] [Abstract][Full Text] [Related]
7. Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients.
Xu X; Yu Y; Shen M; Liu M; Wu S; Liang L; Huang F; Zhang C; Guo W; Liu T
BMC Cancer; 2020 Oct; 20(1):1006. PubMed ID: 33066758
[TBL] [Abstract][Full Text] [Related]
8. Clinical Utility of Plasma Cell-Free DNA in Adult Patients with Newly Diagnosed Glioblastoma: A Pilot Prospective Study.
Bagley SJ; Nabavizadeh SA; Mays JJ; Till JE; Ware JB; Levy S; Sarchiapone W; Hussain J; Prior T; Guiry S; Christensen T; Yee SS; Nasrallah MP; Morrissette JJD; Binder ZA; O'Rourke DM; Cucchiara AJ; Brem S; Desai AS; Carpenter EL
Clin Cancer Res; 2020 Jan; 26(2):397-407. PubMed ID: 31666247
[TBL] [Abstract][Full Text] [Related]
9. High-Sensitivity Mutation Analysis of Cell-Free DNA for Disease Monitoring in Endometrial Cancer.
Ashley CW; Selenica P; Patel J; Wu M; Nincevic J; Lakhman Y; Zhou Q; Shah RH; Berger MF; Da Cruz Paula A; Brown DN; Marra A; Iasonos A; Momeni-Boroujeni A; Alektiar KM; Long Roche K; Zivanovic O; Mueller JJ; Zamarin D; Broach VA; Sonoda Y; Leitao MM; Friedman CF; Jewell E; Reis-Filho JS; Ellenson LH; Aghajanian C; Abu-Rustum NR; Cadoo K; Weigelt B
Clin Cancer Res; 2023 Jan; 29(2):410-421. PubMed ID: 36007103
[TBL] [Abstract][Full Text] [Related]
10. Cell-free circulating tumor DNA in patients with high-grade glioma as diagnostic biomarker - A guide to future directive.
Ahmed KI; Govardhan HB; Roy M; Naveen T; Siddanna P; Sridhar P; Suma MN; Nelson N
Indian J Cancer; 2019; 56(1):65-69. PubMed ID: 30950448
[TBL] [Abstract][Full Text] [Related]
11. Identification of Potential Genomic Alterations Using Pan-Cancer Cell-Free DNA Next-Generation Sequencing in Patients With Gastric Cancer.
Kim B; Kim Y; Cho JY; Lee KA
Ann Lab Med; 2024 Mar; 44(2):164-173. PubMed ID: 37903652
[TBL] [Abstract][Full Text] [Related]
12. Identification of Somatic Mutations in Thirty-year-old Serum Cell-free DNA From Patients With Breast Cancer: A Feasibility Study.
Ritter M; Paradiso V; Widmer P; Garofoli A; Quagliata L; Eppenberger-Castori S; Soysal SD; Muenst S; Ng CKY; Piscuoglio S; Weber W; Weber WP
Clin Breast Cancer; 2020 Oct; 20(5):413-421.e1. PubMed ID: 32650988
[TBL] [Abstract][Full Text] [Related]
13. Cross-platform comparison of next-generation sequencing and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for detecting KRAS/NRAS/BRAF/PIK3CA mutations in cfDNA from metastatic colorectal cancer patients.
Xu X; Huang F; Cao M; Chen X; Wang H; Jiang H; Yu Y; Shen M; Yang Y; Wang B; Liu T; Guo W
J Clin Lab Anal; 2021 Sep; 35(9):e23818. PubMed ID: 34403504
[TBL] [Abstract][Full Text] [Related]
14. Cell-Free DNA Variables including Gene Mutations in CA15-3 Normal Breast Cancer Reflect Prognosis.
Xu J; Chen W; Sun Z; Peng H; Zhou C; Pan S
Dis Markers; 2022; 2022():5470166. PubMed ID: 35251373
[TBL] [Abstract][Full Text] [Related]
15. Plasma Cell-Free DNA in Uterine Cervical Cancer: Therapeutic Monitoring and Prognostic Values after Radical Radiotherapy.
Kim JS; Yang S; Jeong K; Kim DY; Kim K; Kang HC
Cancer Res Treat; 2023 Apr; 55(2):659-670. PubMed ID: 36510654
[TBL] [Abstract][Full Text] [Related]
16. Multi-region sequencing reveals genetic correlation between esophageal squamous cell carcinoma and matched cell-free DNA.
Yuan Z; Wang X; Geng X; Li Y; Tan F; Xue Q; Gao S; He J
Cancer Genet; 2021 Nov; 258-259():93-100. PubMed ID: 34688997
[TBL] [Abstract][Full Text] [Related]
17. Next-generation sequencing for tumor mutation quantification using liquid biopsies.
Provencio M; Pérez-Barrios C; Barquin M; Calvo V; Franco F; Sánchez E; Sánchez R; Marsden D; Cristóbal Sánchez J; Martin Acosta P; Laza-Briviesca R; Cruz-Bermúdez A; Romero A
Clin Chem Lab Med; 2020 Jan; 58(2):306-313. PubMed ID: 31469650
[TBL] [Abstract][Full Text] [Related]
18. Bile cell‑free DNA as a novel and powerful liquid biopsy for detecting somatic variants in biliary tract cancer.
Shen N; Zhang D; Yin L; Qiu Y; Liu J; Yu W; Fu X; Zhu B; Xu X; Duan A; Chen Z; Wang X; Cao X; Zhao T; Zhou Z; Yu L; Qin H; Fang Z; Li JY; Liu Y; Xiong L; Yuan B; Li F; Zhang Y
Oncol Rep; 2019 Aug; 42(2):549-560. PubMed ID: 31173267
[TBL] [Abstract][Full Text] [Related]
19. The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIs.
Del Re M; Crucitta S; Paolieri F; Cucchiara F; Verzoni E; Bloise F; Ciampi R; Mercinelli C; Capuano A; Sportiello L; Martinetti A; Procopio G; Galli L; Porta C; Bracarda S; Danesi R
J Transl Med; 2022 Aug; 20(1):371. PubMed ID: 35974365
[TBL] [Abstract][Full Text] [Related]
20. Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma.
Kotecha RR; Gedvilaite E; Ptashkin R; Knezevic A; Murray S; Johnson I; Shapnik N; Feldman DR; Carlo MI; Shah NJ; Dunigan M; Huberman K; Benayed R; Zehir A; Berger MF; Ladanyi M; Tsui DWY; Motzer RJ; Lee CH; Voss MH
JCO Precis Oncol; 2022 Jul; 6():e2200012. PubMed ID: 35797508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
